Things To Do In SW Florida

By ADRIANA GOMEZ LICON and AMELIA THOMSON-DEVEAUX, Associated Press

FORT LAUDERDALE, Fla. (AP) — As President Donald Trump’s administration imposes new restrictions on the legal immigration system, U.S. adults are more likely than they were a year ago to think these immigrants benefit the country, according to a new poll.

The survey from The Associated Press-NORC Center for Public Affairs Research finds that Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to economic growth and help American companies get the expertise of skilled workers. The survey also shows that Americans are less likely than they were in January to say the number of legal immigrants to the U.S. should be reduced. Slightly fewer than half of Americans say the number should remain the same, a similar percentage from earlier this year.

Related Articles

Build-A-Bear continues to rack up market gains, despite tariffs and teetering mall traffic read more

By TOM MURPHY and MICHELLE CHAPMAN, Associated Press

President Donald Trump blasted Tylenol this week, promoting unproven links between the pain reliever and autism and pushing the well-established treatment into another national image crisis.

“Don’t take Tylenol,” Trump instructed pregnant women around a dozen times during a White House news conference. He also urged mothers not to give infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in other countries.

The attack on Tylenol by the U.S. president was unprecedented but not exactly new territory for one of the world’s most common pain relievers. Tylenol already has faced dozens of lawsuits regarding the autism claim, and it dealt with cyanide poisoning s in the 1980s that lead to a product recall.

Some studies have raised the possibility that taking the over-the-counter painkiller in pregnancy might be associated with a risk of autism — but many others haven’t found a connection.

The attack from Trump could invite more litigation and lead customers to switch to alternatives. But the maker of Tylenol, Kenvue Inc., is refuting Trump’s challenge, and analysts think loyalty to a product that has been on the market since the 1950s may ultimately limit damage. read more

In a landmark deal that bids to resolve a long-running dispute, the Orange County School Board and Town of Eatonville have agreed to sell the Hungerford property to Dr. Phillips Charities as part of an ambitious effort to revitalize the historic enclave.

The property spans 117 acres across two parcels and serves as a gateway into the town that was founded during Reconstruction by freed slaves and is recognized as the first self-governing, all-Black municipality in the United States.

The agreement, shared exclusively with GrowthSpotter, is scheduled for a vote during the Sep. 30 school board meeting. It has the full support of Eatonville Mayor Angie Gardner, who said the pivotal land transfer would safeguard the community from predatory development and set the stage for a resident-driven vision of inclusive, sustainable growth with affordable housing, educational and cultural opportunities and local businesses that honors the town’s deep cultural legacy.

Ken Robinson, President and CEO of Dr. Phillips Charities, said the organization is not seeking to profit from the transaction. He thanked the town and school leaders for trusting the charity to serve as stewards of the historic property. read more

By TOM MURPHY

Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition.

Related Articles

• 
  Powell signals Federal Reserve to move slowly on interest rate cuts

• 
  US stocks slip as Wall Street’s relentless rally takes a pause

• 
  Mars-bound satellites arrive to KSC ahead of Blue Origin launch

• 
  Fed rate trimmed: What does it mean for you?

• 
  More Americans think companies benefit from legal immigration, a new poll finds

The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera. That represents a premium of more than 42% to Metsera’s closing price Friday.

Pfizer also could pay an additional $22.50 per share depending on how Metsera’s product pipeline develops.

Metsera Inc. has no products on the market, but its pipeline includes four programs in clinical development and one in mid-stage testing. Pfizer said the deal will add expertise and potential oral and injectable treatments. read more

By GENE JOHNSON and SALLY HO, Associated Press

SEATTLE (AP) — A federal trial beginning in Amazon’s hometown this week is set to examine whether the online retailing giant tricked customers into signing up for its Prime service and made it difficult to cancel after they did so.

The Federal Trade Commission sued Amazon in U.S. District Court in Seattle two years ago and has alleged more than a decade of legal violations, including of the Restore Online Shoppers’ Confidence Act, a 2010 law designed to help ensure that people know what they’re being charged for online.

Jury selection began Monday, with opening statements to follow.

Related Articles

Disney World picks ambassadors for 2026, 2027

Seattle, a coffee haven, is watching java prices spike. Why?

Florida is set to end business rent tax; state has many new laws hitting the books

Spirit Airlines to furlough 1,800 flight attendants amid second bankruptcy

Compass to buy rival brokerage operator Anywhere Real Estate for about $1.5 billion read more